UPDATE: ²²⁵Ac-LNC1011 Achieves 86.7% PSA50 Response in Early mCRPC Study

/in , , /by

New results presented at EANM 2026 provide further evidence of the preliminary clinical activity of ²²⁵Ac-LNC1011, an experimental PSMA-targeted alpha radioligand therapy for metastatic castration-resistant prostate cancer (mCRPC). We have previously discussed this therapy in this post. Following the initial results, the new prospective study includes 15 patients previously treated with androgen receptor pathway inhibitors […]

Read more

Phase 1 Trial Investigates MAO-A Inhibition With ITR-251 to Overcome Prostate Cancer Resistance

/in , , /by

A new Phase 1 clinical trial  will investigate ITR-251, an experimental inhibitor of monoamine oxidase A (MAO-A), as a potential treatment for advanced solid tumours and metastatic castration-resistant prostate cancer (mCRPC). What makes this investigation unusual is its molecular target. MAO-A is an enzyme best known for breaking down neurotransmitters and other monoamines. However, research […]

Read more

Phase 1/2 Trial Combines GI-102 With Pasritamig to Strengthen T-Cell Immunotherapy in Advanced Prostate Cancer

/in , , , /by

A newly registered phase 1/2 clinical trial will investigate whether combining two immunotherapies with complementary mechanisms can improve treatment outcomes in men with metastatic castration-resistant prostate cancer (mCRPC). The study, known as JET-201, plans to enrol 107 patients in the United States and South Korea. The combination brings together pasritamig (JNJ-78278343), a bispecific antibody designed […]

Read more

UPDATE: VIR-5500 Receives FDA Fast Track Designation Following Promising Phase 1 Results in mCRPC / mAPMR

/in , , /by

The US Food and Drug Administration (FDA) has granted Fast Track designation to VIR-5500 (formerly AMX-500), an experimental immunotherapy for patients with heavily pretreated metastatic castration-resistant prostate cancer (mCRPC). The designation is intended to accelerate clinical development and regulatory review, but does not constitute drug approval. VIR-5500 is a bispecific T-cell engager designed to direct […]

Read more

Phase 1 Trial for KMV002, a New Prostate Cancer Vaccine for mCRPC

/in , , /by

A new phase 1  clinical trial will investigate KMV002, an experimental therapeutic cancer vaccine for patients with metastatic prostate cancer that has become resistant to androgen-targeting treatments (mAPMR, previously mCRPC). Patients will receive either five or six doses of KMV002, a combination of SN3001C and an immune-stimulating substance known as a CpG ODN adjuvant. KMV002, […]

Read more

Phase 1/2 Trial: REGN21353 Plus Nezastomig STEAP1×CD3 and PSMA×CD28 Combination Enters mCRPC Trials

/in , , , /by

A new phase 1/2 trial will test REGN21353, a STEAP1×CD3 bispecific antibody, alone and in combination with nezastomig (REGN5678), a PSMA×CD28 costimulatory bispecific, in previously treated metastatic castration-resistant prostate cancer mCRPC (metastatic androgen pathway modulation-resistant prostate cancer mAPMR). The approach combines two different prostate cancer antigens and two complementary immune signals: CD3-mediated T-cell activation through […]

Read more

JUR-003 Enters Phase 1 Trial in Metastatic Prostate Cancer

/in , , , , /by

A new first-in-human phase 1 trial, has been posted for JUR-003 in metastatic prostate cancer. The study plans to enrol up to 210 patients and includes dose-escalation and dose-expansion cohorts in mCRPC, metastatic hormone-sensitive prostate cancer (mHSPC) and oligometastatic disease. JUR-003 will be given intravenously, with the initial goals of defining safety, pharmacokinetics and a […]

Read more

Phase 1 Trial for SNV1521 PARP1 Inhibitor in mCRPC aka mAPMR Prostate Cancer

/in , , /by

A next-generation PARP inhibitor called SNV1521 is showing early signs of activity in advanced prostate cancer, while potentially causing less bone-marrow toxicity than existing PARP drugs. SNV1521 is an oral drug designed to selectively inhibit PARP1 while largely sparing PARP2. Current PARP inhibitors such as olaparib inhibit both proteins, and suppression of PARP2 is thought […]

Read more

Phase 1 Trial: JANX007 Plus JANX013 Combo in mCRPC / mAPMR

/in , , /by

A newly registered phase 1 trial is taking an interesting approach to one of the limitations of T-cell engagers in prostate cancer: rather than simply trying to make them more powerful, it will test whether a second immune signal can make their activity more durable. The trial will evaluate JANX007 together with the new drug […]

Read more

Soon to be Phase 1 for ICP-B381, a New Bispecific Antibody-Drug Conjugate for mCPRC

/in , , /by

A new antibody-drug conjugate has received clearance to enter clinical trials in China with a double strategy for prostate cancer: instead of targeting PSMA or STEAP1, ICP-B381 targets both. The experimental bispecific ADC combines a humanised antibody recognising PSMA and STEAP1 with a proprietary cytotoxic payload connected through an irreversible linker. Both proteins are strongly […]

Read more